68 related articles for article (PubMed ID: 11544938)
1. Inflammatory Cytokine Pattern Is Sex-Dependent in Mouse Cutaneous Melanoma Experimental Model.
Surcel M; Constantin C; Caruntu C; Zurac S; Neagu M
J Immunol Res; 2017; 2017():9212134. PubMed ID: 29318162
[TBL] [Abstract][Full Text] [Related]
2. Association of Nonmelanoma Skin Cancers, Melanoma, and Merkel Cell Carcinoma with Dermatologic Medications: A Case-Control Pharmacovigilance Study of the FDA Adverse Events Reporting System.
Jedlowski PM
Dermatology; 2023; 239(5):694-699. PubMed ID: 37054693
[TBL] [Abstract][Full Text] [Related]
3. Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas.
Kim HE; Kim J; Park HK; Lee JB; Yun SJ
Melanoma Res; 2024 Feb; 34(1):38-43. PubMed ID: 37924528
[TBL] [Abstract][Full Text] [Related]
4. Drug therapies in dermatology.
Aslam A; Griffiths CE
Clin Med (Lond); 2014 Feb; 14(1):47-53. PubMed ID: 24532745
[TBL] [Abstract][Full Text] [Related]
5. Cytokines in the Treatment of Cancer.
Conlon KC; Miljkovic MD; Waldmann TA
J Interferon Cytokine Res; 2019 Jan; 39(1):6-21. PubMed ID: 29889594
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor as an antineoplastic agent: pitfalls and promises.
Mueller H
Cell Mol Life Sci; 1998 Dec; 54(12):1291-8. PubMed ID: 9893706
[TBL] [Abstract][Full Text] [Related]
7. Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma.
Tachiki LML; Hippe DS; Silva KW; Hall ET; McCamy W; Fritzsche D; Perdue A; Majovski J; Pulliam T; Goldstein DA; Veatch J; Ho J; Nghiem PT; Thompson JA; Bhatia S
Cancer Immunol Immunother; 2023 Dec; 72(12):4471. PubMed ID: 37979010
[No Abstract] [Full Text] [Related]
8. [Role of MHC class I molecules in anti-tumoral mechanisms in human malignant melanoma].
Dissemond J; Grabbe S
Hautarzt; 2006 Aug; 57(8):690-6. PubMed ID: 16163561
[TBL] [Abstract][Full Text] [Related]
9. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.
Yurkovetsky ZR; Kirkwood JM; Edington HD; Marrangoni AM; Velikokhatnaya L; Winans MT; Gorelik E; Lokshin AE
Clin Cancer Res; 2007 Apr; 13(8):2422-8. PubMed ID: 17438101
[TBL] [Abstract][Full Text] [Related]
10. [Cytokines: current status and prospects in the treatment of skin tumors].
Nashan D; Luger TA
Hautarzt; 2001 Aug; 52(8):691-6. PubMed ID: 11544938
[TBL] [Abstract][Full Text] [Related]
11. Medical management of cutaneous malignancies.
Gibbs P; Gonzalez R; Lee LA; Walsh P
Clin Dermatol; 2001; 19(3):298-304. PubMed ID: 11479042
[No Abstract] [Full Text] [Related]
12. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.
Komatsubara KM; Jeter J; Carvajal RD; Margolin K; Schadendorf D; Hauschild A
Am Soc Clin Oncol Educ Book; 2017; 37():641-650. PubMed ID: 28561682
[TBL] [Abstract][Full Text] [Related]
13. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]